ClinicalTrials.gg
WithdrawnNCT07570966Updated Jun 22, 2026

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase 1/2 interventional study of ERW316 and Fulvestrant in Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors and Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 199 studies in Breast Neoplasms by Novartis — 16 open to participants now, 30 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Enrollment
152nd of 155
0 · median 104
Started
2026
with 9 others
Phase 1/2
12 of 199
2 open now
Registered
192nd of 199
by date

Among the 199 studies in Breast Neoplasms by Novartis, this one is the 152nd largest by enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2026, is one of 12 in phase 1/2, and was the 192nd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 199 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.

Phase II: Further characterize the safety and tolerability of ERW316 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Read the detailed description

This is a first-in-human, open-label, Phase I/II, multi-center study consisting of an ERW316 single agent arm in patients with advanced HR+/HER2- breast cancer, other advanced solid tumors harboring CCNE1 amplification, and metastatic castration-resistant prostate cancer, and a combination treatment arm of ERW316 with fulvestrant or letrozole in patients with advanced HR+/HER2- breast cancer. Single agent escalation may be followed by an expansion part stratified by disease indication. The escalation of the fulvestrant combination arm may continue into a randomized, open-label, Phase II with optional dose optimization in advanced HR+/HER2- breast cancer patients.

03

Conditions studied

  • Advanced HR+/HER2- Breast Cancer
  • Advanced CCNE1-amplified Solid Tumors
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Keywords

  • ERW316
  • fulvestrant
  • letrozole
  • hormone receptor positive
  • HER-2 negative
  • Breast cancer
  • CCNE1 amplification
  • Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • (ECOG) performance status of ≤ 1.
  • Patients with one of the following or cytologically confirmed advanced cancers:

Phase I (patients with one of the following cancers, for whom no standard therapy is available or appropriate in the judgment of the investigator):

  • HR+/- advanced breast cancer (aBC) with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional for disease.
  • Locally advanced or metastatic cancer with CCNE1- amplification. For dose expansion only: no more than 5 prior lines of therapy (ovarian cancer) or 3 prior lines of therapy (gastric or esophageal adenocarcinoma).
  • Metastatic castration-resistant prostate adenocarcinoma (mCRPC), with no documented neuroendocrine component, castrate level of testosterone, disease progression on or after at least one line of androgen receptor pathway inhibitor therapy (ARPI) and at least one line of taxane-based chemotherapy, and no more than 3 total prior lines of systemic therapy for metastatic disease.

Phase II:

  • HR+/HER2- aBC with disease progression on or after an endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease, with no more than 2 total lines of endocrine therapy and no prior cytotoxic chemotherapy or antibody-drug conjugate therapy for advanced disease.

Phase I and Phase II:

- as determined by v1.1, with the following exceptions: aBC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment.

mCRPC only: If no measurable disease is present per PCWG3 modified RECIST, then at least one metastatic lesion must be present on bone scan imaging

Exclusion criteria

Exclusion Criteria:

  • Patients with inadequate bone marrow and/or organ function
  • Presence of symptomatic central nervous system (CNS) or that require local therapy or increasing doses of within 2 weeks prior to study entry.
  • Patients with symptomatic visceral disease, including visceral crisis.
  • For patients with breast cancer only: Patient is concurrently using hormone replacement therapy.
  • Women of (WOCBP) who are unwilling to use highly effective methods
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase I: ERW316 single agent (Arm A)

    ERW316

    Drug: ERW316

  • Experimental
    Phase I: ERW316 in combination with Fulvestrant (Arm B)

    ERW316 in combination with fulvestrant.

    Drug: ERW316 · Drug: Fulvestrant

  • Experimental
    Phase I: ERW316 in combination with letrozole (Arm C)

    ERW316 in combination with letrozole.

    Drug: ERW316 · Drug: Letrozole

  • Experimental
    Phase II, recommended dose (RD)-1: ERW316 in combination with Fulvestrant (Arm D)

    ERW316 in combination with fulvestrant.

    Drug: ERW316 · Drug: Fulvestrant

  • Experimental
    Phase II, RD-2 (optional dose optimization): ERW316 in combination with Fulvestrant (Arm E)

    ERW316 in combination with fulvestrant.

    Drug: ERW316 · Drug: Fulvestrant

Interventions

  • DrugERW316

    Oral administration

  • Intramuscular injection. Approved medication.

    Also known as: Faslodex

  • Oral administration. Approved medication.

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence and severity of dose-limiting toxicities (DLTs)

    Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3, unless clearly and inconvertibly assessed as due to disease progression, inter-current illness/injury, concomitant medications, or extraneous causes, that occurs within the first 28 days of treatment in the Phase I part. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: 28 days

  2. Phase I and Phase II: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs, including changes in laboratory values, vital signs and echocardiograms (ECGs) qualifying and reported as AEs.

    Time frame: Up to approximately 2 years

  3. Phase I and Phase II: Frequency of dose interruptions, reductions and discontinuations

    Number of participants with dose adjustments (interruptions, reductions, or permanent discontinuation) as a measure of tolerability.

    Time frame: Up to approximately 2 years

  4. Phase I and Phase II: Dose intensity

    Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Phase I and Phase II: Best Overall Response (BOR)

    BOR per RECIST v1.1 is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first. Efficacy will be based on the investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or Prostate Cancer Working Group 3 (PCWG3) criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  2. Phase I and Phase II: Overall Response Rate (ORR)

    ORR per RECIST v1.1 is defined as the proportion of patients with a BOR of Complete response (CR) or Partial response (PR). Efficacy will be based on the investigator assessment per RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  3. Phase I and Phase II: Disease Control Rate (DCR)

    DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable disease (SD). Efficacy will be based on the investigator assessment per RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  4. Phase I and Phase II: Clinical Benefit Rate (CBR)

    CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks. Efficacy will be based on the investigator assessment per RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  5. Phase I and Phase II: Progression Free Survival (PFS)

    PFS per RECIST 1.1 is defined as the time from the date of start of study treatment (Phase I) or the date of randomization (Phase II) to the date of the first documented progression or death due to any cause. Efficacy will be based on the investigator assessment per RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  6. Phase II: Duration of Response (DOR)

    DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression by local review as applicable or death due to any cause. Efficacy will be based on the investigator assessment per RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1 (only for patients with prostate cancer).

    Time frame: Up to approximately 2 years

  7. Phase I and Phase II: Area under the plasma concentration-time curve (AUC) of ERW316

    Pharmacokinetic (PK) parameters based on plasma concentrations of ERW316.

    Time frame: From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 22. 1 cycle = 28 days

  8. Phase I and Phase II: Maximum plasma concentration (Cmax) of ERW316

    PK parameters based on plasma concentrations of ERW316.

    Time frame: From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 22. 1 cycle = 28 days

  9. Phase I and Phase II: Time to reach maximum plasma concentration (Tmax) of ERW316

    PK parameters based on plasma concentrations of ERW316.

    Time frame: From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 22. 1 cycle = 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Aug 2031, 61 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Aug 1, 2031
CompletionEst.
Aug 1, 2031
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570966
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Aug 1, 2031 (estimated)
Completion
Aug 1, 2031 (estimated)
Last update
Jun 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion